You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

How Does Gastric Sleeve Compare With Gastric Bypass After 5 Years?

  • Authors: MDEdge News Author: Jim Kling; CME Author: Laurie Barclay, MD
  • CME / ABIM MOC / CE Released: 12/17/2021
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 12/17/2022, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for gastroenterologists, general surgeons, diabetologists/endocrinologists, internists, family medicine/primary care clinicians, pediatricians, obstetricians/gynecologists, family medicine practitioners, nurses, , public health officials, and other members of the health care team who treat and manage patients needing bariatric surgery.

The goal of this activity is to describe the comparative risk for mortality, complications, reintervention, and health care use 5 years after sleeve gastrectomy and gastric bypass, based on a retrospective cohort study of adults in a national Medicare claims database.

Upon completion of this activity, participants will:

  • Assess the comparative risk for mortality, complications, reintervention, and health care use 5 years after sleeve gastrectomy and gastric bypass, based on a retrospective cohort study of adults in a national Medicare claims database
  • Evaluate the clinical implications of the comparative risk for mortality, complications, reintervention, and health care use 5 years after sleeve gastrectomy and gastric bypass, based on a retrospective cohort study of adults in a national Medicare claims database
  • Outline implications for the healthcare team


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


MDEdge News Author

  • Jim Kling

    Disclosures

    Disclosure: Jim Kling has disclosed no relevant financial relationships.

CME Author

  • Laurie Barclay, MD

    Freelance writer and reviewer
    Medscape, LLC

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

Editor/CME Reviewer/Nurse Planner

  • Leigh A. Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance
    Medscape, LLC

    Disclosures

    Disclosure: Leigh A. Schmidt, MSN, RN, CMSRN, CNE, CHCP, has disclosed no relevant financial relationships.

CE Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance
    Medscape, LLC

    Disclosures

    Disclosure: Amanda Jett, PharmD, BCACP, has disclosed no relevant financial relationships.

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

How Does Gastric Sleeve Compare With Gastric Bypass After 5 Years?

Authors: MDEdge News Author: Jim Kling; CME Author: Laurie Barclay, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 12/17/2021

Valid for credit through: 12/17/2022, 11:59 PM EST

processing....

Clinical Context

Sleeve gastrectomy accounts for more than 60% of all bariatric procedures and has an excellent short-term safety profile, efficacy for weight loss and comorbidities, and technical ease compared with gastric bypass. It is also considered safe for high-risk patients, including older patients with multiple comorbidities.

Study Synopsis and Perspective

Five years out, sleeve gastrectomy had a lower risk for mortality, complications, and reinterventions than gastric bypass, but there was a higher risk for surgical revision, including conversion to another bariatric surgery, gastrectomy, or anastomotic revision, according to a new analysis.

Sleeve gastrectomy has gained rapid popularity and now represents 60% of all bariatric procedures. It has demonstrated good efficacy and short-term safety, it is easier to perform than laparoscopic Roux-en-Y gastric bypass, and it is a safe option for high-risk patients, authors led by Ryan Howard, MD, from the University of Michigan, Ann Arbor, wrote in JAMA Surgery.[1]

Still, there are few comparative data on the long-term efficacy of the 2 procedures. Randomized controlled trials have conducted long-term follow-up, but their small size has made it difficult to detect differences in rare outcomes. Observational studies are limited by the potential for bias. A novel approach to limiting bias is instrumental variables analysis, which controls for possible confounding using a factor that affects treatment choice, but not patient outcome, to control for possible confounders. Studies using this approach confirmed the superior safety profile of sleeve gastrectomy in the short term.

The current study's authors used that method to examine 5-year outcomes in a Medicare population in which obesity and its complications are especially frequent. Partly because of that lack of data, the Medicare Evidence Development and Coverage Committee has called for more data in older patients and in patients with disabilities.

The researchers analyzed data from 95,405 Medicare claims between 2012 and 2018, using state-level variation in sleeve gastrectomy as the instrumental variable.

At 5 years, sleeve gastrectomy was associated with a lower cumulative frequency of mortality (4.27% [95% confidence interval (CI), 4.25%-4.30%] vs 5.67% [95% CI, 5.63%-5.69%]), complications (22.10% [95% CI, 22.06%-22.13%] vs 29.03% [95% CI, 28.99%-29.08%]), and reintervention (25.23% [95% CI, 25.19%-25.27%] vs. 33.57% [95% CI, 33.52%-33.63%]). At 5 years, surgical revision was more common in the sleeve gastrectomy group (2.91% [95% CI, 2.90%-2.93%] vs 1.46% [95% CI, 1.45%-1.47%]).

The sleeve gastrectomy group had lower odds of all-cause hospitalization at 1 year (adjusted hazard ratio, 0.83; 95% CI, 0.80-0.86) and 3 years (aHR, 0.94; 95% CI, 0.90-0.98), as well as emergency department use at 1 year (aHR, 0.87; 95% CI, 0.84-0.90) and 3 years (aHR, 0.93; 95% CI, 0.90-0.97). There was no significant difference between the 2 groups at 5 years with respect to either outcome.

The effort to understand the long-term outcomes of these 2 procedures has been challenging because follow-up is often incomplete and because reporting is not always standardized, according to Anita P. Courcoulas, MD, MPH, and Bestoun Ahmed, MD, who wrote an accompanying editorial.[2] They noted that the differences in mortality is a new finding and the difference in surgical revisions confirmed something often seen in clinical practice. "Overall, these novel methods, which creatively balance unmeasured factors, have succeeded in providing important incremental findings about the long-term comparative safety outcomes between bariatric procedures that will be helpful in clinical practice," the editorial authors wrote.

The complications discussed in the study are also difficult to interpret, according to Ali Aminian, MD, who is a professor of surgery and director of Bariatric and Metabolic Institute at Cleveland Clinic in Ohio. They may be related to the surgery or may be complications that accrue as patients age. "So that doesn't mean those were surgical complications, but [the findings are] in line with the other literature that [gastric sleeve] may be safer than gastric bypass, but in a different cohort of patients," said Dr Aminian, who was asked to comment.

"I thought it validated that which many of us in clinical practice see on a day-to-day basis," said Shanu Kothari, MD, chair of surgery at Prisma Health in Greenville, South Carolina, and the current president of American Society for Bariatric and Metabolic Surgery. He pointed out that the study was limited by its reliance on administrative claims, which makes it impossible to know the reduction in weight and obesity-related comorbid conditions after the procedures, as well as factors driving individual decisions: A surgeon might offer sleeve to a patient at higher risk for complications, but a gastric bypass to someone with more comorbidities. "What we don't know is how to interpret this 35,000-foot view of Medicare data to that conversation with the patient sitting right in front of you," said Dr Kothari.

The authors similarly cited the "lack of clinical granularity in administrative claims data" among study limitations, as well as how the use of instrumental variables may leave the findings less applicable to patients more strongly indicated for one procedure over the other.

"Longer-term randomized clinical trials and observational studies are warranted to confirm these findings," the study authors concluded. "Understanding the risk profile of various bariatric operations may further help patients and surgeons make the most appropriate decisions regarding plans of care."

The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases. Some study authors and editorialists reported funding from various groups and institutions, such as the National Institutes of Health and the VA Ann Arbor Health System. Dr Kothari and Dr Aminian have disclosed no relevant financial relationships.

JAMA Surg. Published online October 06, 2021.

Study Highlights

  • This retrospective cohort study included 95,405 adult patients in a national Medicare claims database who had laparoscopic sleeve gastrectomy (57,003; 60%) or laparoscopic Roux-en-Y gastric bypass (38,402; 40%) from January 1, 2012, to December 31, 2018.
  • Cumulative incidence of outcomes up to 5 years after surgery was estimated with instrumental variables survival analysis.
  • Patients undergoing sleeve gastrectomy had mean age of 57.1±11.8 years, 74.2% were women, 0.2% were Asian, 17.7% were Black, 3.4% were Hispanic, 0.6% were North American Native, 75.8% were White, 0.9% were of other race/ethnicity, and 1.4% were of unknown race/ethnicity.
  • For gastric bypass, mean age was 55.9±11.7, 75.7% were women, 0.3% were Asian, 15.7% were Black, 3.2% were Hispanic, 0.7% were North American Native, 78.1% were White, 1.0% were of other race/ethnicity, and 1.1% were of unknown race/ethnicity.
  • At 5 years after surgery, patients undergoing sleeve gastrectomy vs gastric bypass had lower cumulative incidence of mortality (4.27% [95% CI, 4.25%-4.30%] vs 5.67% [95% CI, 5.63%-5.69%]), complications (22.10% [95% CI, 22.06%-22.13%] vs 29.03% [95% CI, 28.99%-29.08%]), and reintervention (25.23% [95% CI, 25.19%-25.27%] vs 33.57% [95% CI, 33.52%-33.63%]).
  • However, patients undergoing sleeve gastrectomy had higher cumulative incidence of surgical revision at 5 years (2.91% [95% CI, 2.90%-2.93%] vs 1.46% [95% CI, 1.45%-1.47%]).
  • They also had lower aHR of all-cause hospitalization (0.83; 95% CI, 0.80-0.86) and ED use (0.87; 95% CI, 0.84-0.90) at 1 year and 3 years (0.94 [95% CI, 0.90-0.98] for hospitalization and 0.93 [95% CI, 0.90-0.97] for ED use) after surgery, but with no significant between-group difference at 5 years.
  • Total health care spending among patients undergoing sleeve gastrectomy was lower at 1 year postoperatively ($28,706 [95% CI, $27,866-$29,545] vs $30,663 [95% CI, $29,739-$31,587]), but similar between groups at 3 years ($57,411 [95% CI, $55,239-$59,584] vs $58,581 [95% CI, $56,551-$60,611]) and 5 years ($86,584 [95% CI, $80,183-$92,984] vs $85,762 [95% CI, $82,600-$88,924]).
  • The investigators concluded that in this large cohort, sleeve gastrectomy was associated with lower long-term risk for mortality, complications, and reinterventions but higher long-term risk for surgical revision.
  • Understanding the comparative safety of these operations, with safety benefits of sleeve gastrectomy persisting up to 5 years postoperatively, may better inform treatment decision-making of patients and surgeons.
  • Use of instrumental variables analysis in this study limited bias by controlling for possible confounding, using a factor affecting treatment choice but not outcome.
  • The absolute difference in 5-year mortality of 1.4 percentage points translates to a 32.8% relative difference in mortality between the 2 procedures and a number needed to harm of 71.
  • Increased incidence of complications after gastric bypass may drive increased mortality risk, as suggested by other large observational studies.
  • However, increased mortality with bypass should be weighed against potential benefits, including superior weight loss and lower incidence of surgical revision.
  • Although safety benefits of sleeve gastrectomy may be generalizable to older patients, their risk for revision may be less significant.
  • Study limitations include reliance on administrative claims and lack of data on weight loss, comorbidity resolution, and medication discontinuation after surgery.
  • Longer-term randomized clinical trials and observational studies are therefore needed for confirmation and clarification of competing risks and benefits of these two procedures.
  • An accompanying editorial noted that differences in mortality is a new finding and that the difference in surgical revisions confirmed clinical experience.

Clinical Implications

  • Gastric sleeve vs bypass had lower long-term risk for death, complications, and reinterventions, but higher risk for surgical revision.
  • Understanding the comparative safety of these operations may better inform treatment decision-making.
  • Implications for the Health Care Team: Increased mortality with bypass should be weighed against potential benefits, including superior weight loss and lower incidence of surgical revision.

 

Earn Credit

  • Print